AGM/EGMJun 23, 2026, 07:51 AM
Cardiol Therapeutics to Webcast Virtual AGM on June 24th
AI Summary
Cardiol Therapeutics Inc. announced it will webcast its virtual Annual General Meeting of Shareholders on June 24th at 4:30 PM EDT. The company, a late-stage life sciences firm, is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, currently in a pivotal Phase III trial for recurrent pericarditis. CardiolRx™ has received U.S. FDA Orphan Drug Designation for pericarditis, and the company is also developing CRD-38 for inflammatory heart disease.
Key Highlights
- Cardiol Therapeutics to webcast its virtual Annual General Meeting of Shareholders.
- The AGM is scheduled for June 24th at 4:30 PM EDT.
- Information to participate and vote is available on the Company's website.
- Company focuses on anti-inflammatory and anti-fibrotic therapies for heart disease.
- Lead drug candidate, CardiolRx™, modulates inflammasome pathway activation.
- MAVERIC Program includes ongoing pivotal Phase III MAVERIC trial for recurrent pericarditis.
- CardiolRx™ has U.S. FDA Orphan Drug Designation for pericarditis.
- Company is also developing CRD-38 for inflammatory heart disease.
Price Impact
More from CRDL